Klaria strengthens its drug delivery platform with acquisition of innovative technology with potential to revolutionize delivery of large molecules
Klaria announces today that it has acquired WBC Drug Delivery Technologies, a drug delivery company based in Munich, Germany. The company’s technology, discovered at the Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), a branch of the Helmholtz Centre for Infection Research (HZI), has the potential to dramatically facilitate the delivery of large molecules including anti-infectives, vaccines and peptides. Klaria has acquired all shares of WBC Drug Delivery Technologies with 1 301 248 newly issued shares of Klaria Pharma Holding AB.With this acquisition, Klaria adds a